QM-2 Nonpharmacological interventions for ACC/AHA stage 1 HBP Physician group practice, accountable care organization, clinically integrated network, health plan, integrated delivery system Adds new emphasis high-quality evidence and strong recommendation for promoting lifestyle modification, as recommended in the 2017 Hypertension Clinical Practice Guidelines for ACC/ AHA stage 1 population as an important strategy for controlling HBP. QM-3 Nonpharmacological interventions for all ACC/AHA stages of HBP (composite measure combining PM-4, Physician group practice, accountable care organization, clinically integrated network, health plan, integrated delivery system Adds new emphasis on high-quality evidence and strong recommendation for promoting lifestyle modification, as recommended in the 2017 Hypertension Clinical Practice Guidelines for all 3 ACC/AHA stages of HBP population as an important strategy for controlling HBP. Composite measure permits assessment of effectiveness for all stages combined. QM-4 Medication adherence to drug therapy for ACC/AHA stage 1 with ASCVD risk 10% or ACC/AHA stage Physician group practice, accountable care organization, clinically integrated network, health plan, integrated delivery system Adds new emphasis on high-quality evidence and strong recommendation for assessing and promoting medication adherence, as recommended in the 2017 Hypertension Clinical Practice Guidelines for the combined ACC/AHA stage 1 with ASCVD risk 10% and ACC/AHA stage 2 HBP population as an important strategy for controlling HBP. (Continued) 12 QM-5 Use of HBPM for management of ACC/AHA stage 1 HBP Physician group practice, accountable care organization, clinically integrated network, health plan, integrated delivery system Harmonizes with new performance measure PM-5 for ACC/AHA stage 2 HBP. Adds new emphasis on correct measurement of BP by individuals at home or elsewhere outside the clinic setting, as recommended in the 2017 Hypertension Clinical Practice Guidelines for this population as an important strategy for evaluating control of ACC/ AHA stage 1 HBP and ASCVD risk 10%. 